SCHEMBL166683

SCHEMBL166683

C1CC2C[N]CC1C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL678374 0.86
SCHEMBL1636208 0.69
SCHEMBL333980 0.69
SCHEMBL11224535 0.69
SCHEMBL9764703 0.69
SCHEMBL23926890 0.69
SCHEMBL1230616 0.69 SLC22A2 (0.31)
SCHEMBL136714 0.69
SCHEMBL8189 0.69
SCHEMBL6053187 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023247590-A1 TRIAZOLOPYRIDINE AND BENZOISOXAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2023-12-28 WO claimed
US-10053434-B2 Histone deacetylase inhibitors and compositions and methods of use thereof CHDI FOUNDATION, INC. (US) 2018-08-21 US claimed
EP-3291810-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI Foundation, Inc. (US) 2018-03-14 EP claimed
WO-2016179554-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI FOUNDATION, INC. (US) 2016-11-10 WO claimed
US-20160326124-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI FOUNDATION, INC. 2016-11-10 US claimed
WO-2015027058-A2 CYCLOLKYL AMINE COMPOUNDS PREXA PHARMACEUTICALS, INC. (US) 2015-02-26 WO claimed
US-20150057443-A1 Cycloalkyl Amine Compounds PREXA PHARMACEUTICALS, INC. 2015-02-26 US claimed
EP-2611441-A1 BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES F.HOFFMANN-LA ROCHE AG (CH) 2013-07-10 EP claimed
WO-2012028563-A1 BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2012-03-08 WO claimed
US-20120053200-A1 BACE 2 INHIBITORS HOFFMANN-LA ROCHE INC. 2012-03-01 US claimed
US-20040044014-A1 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-03-04 US claimed
WO-2003089439-A1 BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHOD FOR THE PRODUCTION THEREOF BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-10-30 WO claimed
WO-2003087064-A1 CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS UCB, S.A. (BE) 2003-10-23 WO claimed
EP-0852494-A2 PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-07-15 EP claimed
EP-0345627-B1 9-R-azacyclic erythromycin antibiotics ABBOTT LAB (US) 1997-04-16 EP claimed
WO-1997009973-A2 PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-03-20 WO claimed
WO-1996040641-A1 SULFONAMIDE DERIVATIVES AS CELL ADHESION MODULATORS TANABE SEIYAKU CO., LTD. (JP) 1996-12-19 WO claimed
US-5075289-A Improved activity and therapeutic ratios ABBOTT LABORATORIES (US) 1991-12-24 US claimed
EP-0345627-A2 9-R-azacyclic erythromycin antibiotics ABBOTT LABORATORIES (US) 1989-12-13 EP claimed
EP-0317505-A1 Azacycloalkylalkandiphosphonic acids CIBA-GEIGY AG (CH) 1989-05-24 EP claimed